Table 1.
Baseline characteristics of patients
| Characteristics | All (n = 103) | Early treatment (n = 50) | Delayed treatment (n = 53) | p-value |
|---|---|---|---|---|
| Age (years) | 0.7 | |||
| Median | 39 | 40 | 38 | |
| Range | 19–68 | 23–68 | 20–63 | |
| Sex | 0.9 | |||
| Male | 52 | 26 | 26 | |
| Female | 51 | 24 | 27 | |
| Karnofsky performance status | 0.7 | |||
| Median | 100 | 90 | 100 | |
| Range | 60–100 | 60–100 | 70–100 | |
| Site of tumor | 0.7 | |||
| Temporal | 32 | 15 | 17 | |
| Frontal | 52 | 28 | 24 | |
| Parietal | 11 | 5 | 6 | |
| Occipital | 8 | 2 | 6 | |
| RTOG Neurologic Function Status | 0.6 | |||
| 0 | 54 | 25 | 29 | |
| 1 | 33 | 15 | 18 | |
| 2 | 13 | 8 | 5 | |
| 3 | 3 | 2 | 1 | |
| Radiation dose | 0.6 | |||
| 54 Gy/30 fractions | 62 | 32 | 30 | |
| 50.4 Gy/28 fractions | 41 | 18 | 23 | |
| Extension of resection | 0.3 | |||
| Total | 13 | 4 | 9 | |
| Near total | 36 | 13 | 23 | |
| Subtotal | 31 | 15 | 16 | |
| Partial/biopsy | 23 | 18 | 5 | |
| MGMT promoter methylation status | 1.0 | |||
| Methylated | 91 | 46 | 45 | |
| Unmethylated | 3 | 1 | 2 | |
| Unknown | 9 | 3 | 6 | |
| Postoperative residual volume (cm3) | ||||
| Median | 24.2 | 22.5 | 4.5 | 0.001 |
| Range | 0-251.3 | 0-251.3 | 0-26.4 | |
| Target volumes (cm3) | ||||
| Gross tumor volume (GTV) | ||||
| Median | 56.8 | 49.24 | 68.9 | 0.02 |
| Range | 11.4-251.3 | 11.4-251.3 | 29.2-113.4 | |
| Clinical tumor volume (CTV) | ||||
| Median | 166.7 | 164.4 | 176.8 | 0.15 |
| Range | 72.3-437.5 | 72.3-437.5 | 87.5-348.2 | |
| Planning tumor volume (PTV) | ||||
| Median | 226.5 | 211.2 | 234.2 | 0.2 |
| Range | 102.1-541.3 | 102.1-541.3 | 94.6-437.3 |